MedTrace Logo

Dronabinol Treatment for Marijuana Addiction

NCT00217971 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 156

Last updated 2019-04-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if dronabinol decreases the symptoms of marijuana addiction and withdrawal.

Conditions

  • Marijuana Abuse

Interventions

DRUG

Dronabinol

Dronabinol

DRUG

Placebo

placebo

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • New York State Psychiatric Institute

    lead OTHER

Principal Investigators

  • Frances R Levin, MD · New York State Psychiatric Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00217971 on ClinicalTrials.gov